Track record · closed signal

Abbott Laboratories (ABT) — closed signal from October 28, 2025

Partial Published before the outcome was known, scored automatically when the window closed on January 26, 2026.

Predicted vs. what happened

ABT price · publication thesis → realized outcomesplit-adjusted
$127.21 Published $142.48 Target $108.77 Window close $132.03 Peak
$126.00 – $128.00Entry zone — fair-value band
$127.21Published — price the day we called it
$142.48Target — the price the thesis aimed for
$132.03Peak — highest point inside the window, not a realized return
$108.77Window close — end-of-window price, context only

What happened

Partial

Reached 32% of the predicted growth at its peak, without hitting the target.

Peak price
$132.03
peak on November 18, 2025 — not a realized return
Peak gain
+3.8%
peak, from the publication price
Window close
$108.77
end-of-window price, context only
Days to target
Window
October 28, 2025 – January 26, 2026

The thesis — published October 28, 2025

Predicted growth
+12%
over the measurement window
Target price
$142.48
the price the thesis aimed for
Entry zone
$126.00 – $128.00
the fair-value band we waited for
Price at publication
$127.21
published October 28, 2025
Confidence
62%
how strongly the data lined up
Timeframe
Short-term (0–3 months)

Abbott looks like a steady, lower-risk stock that has fallen more than usual, which could offer a short-term opportunity. A major bank kept a $157 target, while another view says shares may be expensive, so balance optimism with care. Strong cash coming in and long-running dividends may help the price drift up over the next 3 months. Trend signs are still weak, so consider starting near the low end and add only if buyer interest improves.

Primary drivers

  • The stock has dropped more than usual, yet the business is steady and resilient
  • A major bank shows confidence and sets a $157 price goal, lifting sentiment
  • Strong free cash and dependable dividends help support the share price
  • Some think shares are pricey, so move carefully and keep positions modest

How it played out

ABT: the 12% target was not reached

Lyra published ABT on 2025-10-28 at $127.21 with an expected 12% short-term rise to $142.48. The thesis pointed to a steady business after a larger-than-usual drop, a major bank's $157 price goal, strong free cash, dependable dividends, and some caution that the shares may already be pricey.

Inside the window, ABT rose to $132.03 on 2025-11-18, a 3.8% peak gain. It stayed below the $142.48 target and never reached it. By 2026-01-26, the stock ended at $108.77. The thesis only partially played out: there was an early rise, but the target missed and the signal ended lower.

What happened during the window

On 2025-11-20, Abbott announced an agreement to acquire Exact Sciences. On 2026-01-22, Abbott reported fourth-quarter and full-year 2025 results and issued its 2026 financial outlook.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Share this receipt

A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.